Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
RA CAPITAL MANAGEMENT, L.P. (CIK 1346824) reported $9.44B across 78 reported positions in its SEC 13F filing for 2026-03-31. Largest positions: ASND ($2.35B, 24.92%), PCVX ($666.8M, 7.07%), RYTM ($579.8M, 6.14%), TYRA ($467.2M, 4.95%), SION ($397.1M, 4.21%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | ASND | ASCENDIS PHARMA A/S - ADR | $2.35B | 24.92% | 10.3M | Hold |
| 2 | PCVX | VAXCYTE INC | $666.8M | 7.07% | 11.5M | Added |
| 3 | RYTM | RHYTHM PHARMACEUTICALS INC | $579.8M | 6.14% | 6.7M | Hold |
| 4 | TYRA | TYRA BIOSCIENCES INC | $467.2M | 4.95% | 12.2M | Hold |
| 5 | SION | SIONNA THERAPEUTICS INC | $397.1M | 4.21% | 9.9M | Hold |
| 6 | EWTX | EDGEWISE THERAPEUTICS INC | $328.5M | 3.48% | 10.4M | Hold |
| 7 | NAMS | NEWAMSTERDAM PHARMA CO NV | $305.7M | 3.24% | 9.6M | Hold |
| 8 | NUVL | NUVALENT INC-A | $259.6M | 2.75% | 2.5M | Added |
| 9 | DNTH | DIANTHUS THERAPEUTICS INC | $219.2M | 2.32% | 2.6M | Added |
| 10 | MLYS | MINERALYS THERAPEUTICS INC | $208.4M | 2.21% | 7.7M | Added |
| 11 | SPYGLASS PHARMA INC | $207.8M | 2.20% | 8.0M | New | |
| 12 | WVE | WAVE LIFE SCIENCES LTD | $195.6M | 2.07% | 27.0M | Added |
| 13 | SEPN | SEPTERNA INC | $168.1M | 1.78% | 7.0M | Hold |
| 14 | IRON | DISC MEDICINE INC | $156.7M | 1.66% | 2.5M | Added |
| 15 | JANX | JANUX THERAPEUTICS INC | $155.5M | 1.65% | 11.2M | Hold |
| 16 | BCRX | BIOCRYST PHARMACEUTICALS INC | $150.7M | 1.60% | 15.8M | Hold |
| 17 | BCAX | BICARA THERAPEUTICS INC | $144.3M | 1.53% | 7.3M | Added |
| 18 | PRAX | PRAXIS PRECISION MEDICINES I | $120.4M | 1.28% | 373,787 | Hold |
| 19 | ZLAB | ZAI LAB LTD-ADR | $107.4M | 1.14% | 5.7M | New |
| 20 | GHRS | GH RESEARCH PLC | $107.9M | 1.14% | 7.7M | Hold |
| 21 | TSHA | TAYSHA GENE THERAPIES INC | $105.3M | 1.12% | 23.6M | Hold |
| 22 | VOR | VOR BIOPHARMA INC | $96.4M | 1.02% | 5.4M | Hold |
| 23 | GERN | GERON CORP | $95.0M | 1.01% | 63.8M | Hold |
| 24 | SPRY | ARS PHARMACEUTICALS INC | $87.2M | 0.92% | 10.9M | Hold |
| 25 | SRPT | SAREPTA THERAPEUTICS INC | $84.9M | 0.90% | 3.9M | New |
Source: SEC Form 13F filings · as of 2026-03-31